Comparative Pharmacology
Head-to-head clinical analysis: A METHAPRED versus CHLOROMYCETIN HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: A METHAPRED versus CHLOROMYCETIN HYDROCORTISONE.
A-METHAPRED vs CHLOROMYCETIN HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methylprednisolone is a synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to modulation of gene expression and suppression of inflammatory mediators such as cytokines, prostaglandins, and leukotrienes. It also induces lipocortin synthesis, inhibits phospholipase A2, and reduces immune cell activity.
Chloromycetin (chloramphenicol) is a bacteriostatic antibiotic that inhibits protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2 and reducing prostaglandin and leukotriene synthesis.
Initial 4-48 mg/day oral in divided doses, tapered. For pulse therapy: 1 g IV daily for 3 days.
Apply 1-2 drops or a small amount (approximately 0.5 cm ribbon) into the affected eye(s) every 3-4 hours, or more frequently as needed. For severe infections, may be used every 2 hours. Not to exceed 6 times daily. Otic: Instill 3-4 drops into the affected ear(s) 2-3 times daily.
None Documented
None Documented
2-3 hours (terminal); clinical effect persists longer due to intracellular receptor binding.
Chloramphenicol: 1.5-4 hours in adults with normal hepatic function; prolonged to 3-7 hours in neonates and up to 15 hours in severe liver disease. Hydrocortisone: 1-2 hours.
Renal (mainly as inactive metabolites); <5% unchanged. Biliary/fecal excretion is minimal.
Renal: ~80-90% of chloramphenicol as inactive metabolites (glucuronide conjugate) and 5-10% unchanged. Biliary: <3% of unchanged drug. Fecal: minimal.
Category C
Category D/X
Corticosteroid
Corticosteroid